FMP
Entera Bio Ltd.
ENTX
NASDAQ
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
2.34 USD
0.11 (4.7%)
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
236k
365k
571k
134k
-
-
-
-
-
-
-8.92M
-10.42M
-9.06M
-12.5M
-7.31M
-
-
-
-
-
-40k
-53k
-17k
-47k
-17k
-
-
-
-
-
-8.96M
-10.48M
-9.08M
-12.55M
-7.33M
-
-
-
-
-
11.88
11.88
11.88
11.88
11.88
-
-
-
-
-
-